Signifier Medical Technologies Announces Conference Participation at CHEST 2022, Medtrade East and Maryland Sleep Society Annual Scientific Conference

BOSTON & LONDON--(BUSINESS WIRE)--Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announced participation in three upcoming medical conferences. At each conference, Signifier will showcase its lead product eXciteOSA®, the only FDA-authorized, non-invasive daytime therapy for primary snoring and mild obstructive sleep apnea. In the company’s booth at each conference, Signifier will have copies available of its recently released white paper, A descriptive analysis of objectively-monitored real-world adherence to eXciteOSA®.

Details for the three conferences include:

• CHEST 2022, the annual meeting of the American College of Chest Physicians
  • Music City Center, Nashville, Tennessee, Booth 1129 in the Exhibit Hall
  • October 16-19
• Medtrade East, the largest home medical equipment trade show and conference in the United States
  • Georgia World Conference Center, Atlanta, Georgia, Booth 1157 in the Exhibit Hall
  • October 24-26

• Maryland Sleep Society’s 12^th Annual Scientific Conference
  • The Sheraton Baltimore North Hotel, Townson, Maryland
  • October 21-22

About Signifier Medical Technologies

Signifier is a pioneer in addressing the root causes of sleep disordered breathing. The Company is focused on the development and commercialization of innovative and non-invasive solutions to help people breathe normally and naturally all night – without needing to use a wearable medical device or a surgical implant. Founded in 2015, Signifier is at the forefront of sleep therapy, with a mission to develop therapies to improve population health, increase the quality of patients’ healthcare experience, and generate healthcare savings. Signifier has offices in London (UK) and Needham (Massachusetts, USA).

About eXciteOSA

eXciteOSA is a revolutionary daytime therapy for sleep disordered breathing. Clinically proven to target a common root cause of OSA, eXciteOSA improves daytime sleepiness and sleep quality. Nearly one billion adults aged 30 to 69 years globally are estimated to suffer from OSA, which is a serious medical condition associated with health problems such as high blood pressure and increased risks of heart attack, stroke, or death.

A major underlying cause of OSA is reduced endurance of the upper airway muscles, allowing the tongue to fall back and block the upper airway. By using neuromuscular electrical stimulation (NMES) to “exercise” the upper airway muscles, eXciteOSA works the intrinsic and extrinsic tongue muscles to improve endurance and prevent airway collapse during sleep.

Unlike other devices which are used while patients sleep, eXciteOSA is the first commercially available device used while awake. The full benefits of the daytime therapy are realized without patient use during sleep.

Signifier is dedicated to engaging with the sleep research community to produce high-quality evidence from rigorous clinical trials. Randomized trials are in progress to understand the potential placebo effect (NCT04974515), the impact of therapy relative to usual care without treatment (NCT05183009; NCT05252156), and the impact of therapy amongst those with moderate OSA (NCT05252156).

For more information, please visit www.signifiermedical.com or www.exciteosa.com.